Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -75.70% is 25% above its 4-year average of -101.06%, near the high end of its 4-year range (-747.65%–-41.97%).
As of the fiscal period ended Tuesday, June 30, 2026. 69.56% above its 12-month average of -248.74%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -75.70%.
RETURN ON EQUITY (ROE)
-75.70%
RETURN ON EQUITY (ROE) AVG TTM
-248.74%
RETURN ON EQUITY (ROE) AVG 3Y
-250.19%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+69.56%
CURRENT VS 3Y AVG
+69.74%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-80.20%
vs the sector median at left
Onconetix, Inc.
Market Cap
$2.37M
Return on Equity (ROE)
-75.70%
TTM Avg
-248.74%
3Y Avg
-250.19%
5Y Avg
N/A
Market Cap
$2.37M
Return on Equity (ROE)
-391.26%
TTM Avg
-355.49%
3Y Avg
-474.62%
5Y Avg
-295.97%
Market Cap
$2.38M
Return on Equity (ROE)
-53.49%
TTM Avg
-904.74%
3Y Avg
-509.27%
5Y Avg
-319.78%
Market Cap
$2.38M
Return on Equity (ROE)
-261.73%
TTM Avg
-293.81%
3Y Avg
-189.35%
5Y Avg
-145.76%
Market Cap
$2.32M
Return on Equity (ROE)
-69.79%
TTM Avg
-83.20%
3Y Avg
-70.37%
5Y Avg
-0.36%
Market Cap
$2.44M
Return on Equity (ROE)
-554.01%
TTM Avg
-109.66%
3Y Avg
1542.76%
5Y Avg
920.25%
Market Cap
$2.54M
Return on Equity (ROE)
-402.92%
TTM Avg
-276.14%
3Y Avg
-197.40%
5Y Avg
-116.89%
Market Cap
$2.56M
Return on Equity (ROE)
N/A
TTM Avg
-419.35%
3Y Avg
-396.40%
5Y Avg
-293.00%
Market Cap
$2.14M
Return on Equity (ROE)
N/A
TTM Avg
642.41%
3Y Avg
-629.18%
5Y Avg
-444.57%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Onconetix, Inc. (ONCO) | $2.37M | -75.70% | -248.74% | -250.19% | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | -391.26% | -355.49% | -474.62% | -295.97% |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | -53.49% | -904.74% | -509.27% | -319.78% |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | -261.73% | -293.81% | -189.35% | -145.76% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -69.79% | -83.20% | -70.37% | -0.36% |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | -554.01% | -109.66% | 1542.76% | 920.25% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -402.92% | -276.14% | -197.40% | -116.89% |
| Nuwellis, Inc. (NUWE)vs › | $2.56M | N/A | -419.35% | -396.40% | -293.00% |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | N/A | 642.41% | -629.18% | -444.57% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | -1160.10% | -528.10% | -389.86% | -336.02% |
ROE
-75.7%
ROA
-62.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -75.70% |
| 2026-03-31 | -82.59% |
| 2025-12-31 | -89.01% |
| 2025-06-30 | -747.65% |
| 2024-12-31 | -610.69% |
| 2024-09-30 | -152.17% |
| 2024-06-30 | -186.89% |
| 2023-09-30 | -178.55% |
| 2023-06-30 | -128.45% |
| 2023-03-31 | -72.08% |
| 2022-12-31 | -59.94% |
| 2022-09-30 | -44.33% |
| 2022-06-30 | -41.97% |
